Stockscreener 앱 받기
3.20
1.91%
0.06
시간 외 거래:
3.20
전일 마감가:
$3.14
열려 있는:
$3.17
하루 거래량:
64,225
Relative Volume:
0.97
시가총액:
$29.14M
수익:
$170.00K
순이익/손실:
$-16.59M
주가수익비율:
-1.6743
EPS:
-1.9113
순현금흐름:
$-15.98M
1주 성능:
+2.56%
1개월 성능:
+0.00%
6개월 성능:
+56.10%
1년 성능:
+18.52%
1일 변동 폭
$3.13
$3.23
1주일 범위
$3.13
$3.23
52주 변동 폭
$1.81
$5.07
Lisata Therapeutics Inc Stock (LSTA) Company Profile
명칭
Lisata Therapeutics Inc
전화
908-229-2590
주소
110 ALLEN ROAD, BASKING RIDGE
Compare LSTA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
LSTA
Lisata Therapeutics Inc
|
3.20 | 28.59M | 170.00K | -16.59M | -15.98M | -1.9113 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lisata Therapeutics Inc 주식(LSTA)의 최신 뉴스
Lisata, Mobileye, VF, Canada Goose, F5 Trending With Analysts - TipRanks
Lisata Therapeutics (LSTA) Holds Steady at $3.14 as Range-Bound Trading PersistsSmart Beta Flow - Newser
LSTA Technical Analysis | Trend, Signals & Chart Patterns | LISATA THERAPEUTICS INC (NASDAQ:LSTA) - ChartMill
What are the Core Details of the Kuva Labs Acquisition of Lisata Therapeutics - Kavout
Lisata Therapeutics (LSTA) Delivers Q3 2025 Beat — EPS $-0.49 vs $-0.55 ExpectedFinancial Summary - Newser
H.C. Wainwright Maintains Lisata Therapeutics(LSTA.US) With Hold Rating - Moomoo
Lisata Therapeutics (LSTA) Climbs +2.92% — Resistance at $3.33 in Focus 2026-05-17Stock Analysis - Newser
LSTA Downgraded by HC Wainwright & Co. -- Rating Changed to Neut - GuruFocus
HC Wainwright Downgrades Lisata Therapeutics to Neutral From Buy - marketscreener.com
H.C. Wainwright downgrades Lisata Therapeutics stock rating to neutral By Investing.com - Investing.com Australia
H.C. Wainwright downgrades Lisata Therapeutics stock rating to neutral - Investing.com
H.C. Wainwright Downgrades Lisata Therapeutics(LSTA.US) to Hold Rating - Moomoo
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: KalVista Pharmaceuticals, Inc. (Nasdaq – KALV), Thermon Group Holdings, Inc. (NYSE – THR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA) - GlobeNewswire Inc.
Lisata Therapeutics (LSTA) Stock Analysis: -2.74% Loss — Key Levels 2026-05-14Crowd Breakout Signals - Newser
Kuva to acquire Lisata (NASDAQ: LSTA) for $5.00 plus $1.00 CVR - Stock Titan
Number of shareholders of Lisata Therapeutics, Inc. – NASDAQ:LSTA - TradingView
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Na - ChartMill
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Esperion Therapeutics, Inc. (Nasdaq – ESPR), Sila Realty Trust, Inc. (NYSE – SILA), Lisata Therapeutics, Inc. (Nasdaq – LSTA), SkyWater Technology, Inc. (Nasdaq - GlobeNewswire Inc.
Lisata Therapeutics, Inc. Announces Amendment and Waiver to Merger Agreement with Kuva Labs Inc. – May 2026 SEC 8-K Filing - Minichart
Kuva Acquisition plans tender offer for Lisata Therapeutics (LSTA) — preliminary filing - Stock Titan
Lisata Therapeutics Amends Kuva Labs Merger Agreement Timeline - TipRanks
Lisata Therapeutics (NASDAQ: LSTA) delays Kuva Labs tender offer to May 29, 2026 - Stock Titan
LSTA Price Today: Lisata Therapeutics, Inc. Stock Price, Quote & Chart | MEXC - MEXC Exchange
Lisata Therapeutics 2025 10-K/A – Executive Compensation, Board Governance, and Change in Control Benefits - Minichart
Executive pay, board structure detailed in Lisata (NASDAQ: LSTA) 10-K amendment - Stock Titan
Lisata Therapeutics Q2 2025 Earnings Preview - MSN
Lisata Therapeutics (LSTA) Market Dynamics | Lisata Therapeutics posts 10.2% EPS beat, 170B revenueExpert Entry Points - Cổng thông tin điện tử tỉnh Lào Cai
Lisata outlines Phase III certepetide trial preparations and targets milestone-rich 2026 amid expanded alliances - MSN
Lisata Therapeutics Inc (LSTA)Valuation Measures & Financial Statistics - GuruFocus
Lisata Therapeutics extends deadline for Kuva tender offer - The Globe and Mail
Lisata Therapeutics says Kuva Labs seeking new financing, tender offer not yet commenced - TradingView
Financing delays put Lisata Therapeutics (LSTA) tender offer by Kuva Labs in doubt - Stock Titan
Lisata Therapeutics posts 10.2% EPS beat, 170B revenueAttention Driven Stocks - Newser
Lisata Therapeutics to be acquired by Kuva Labs in $4.00-per-share cash deal - MSN
Q2 2025 Lisata Therapeutics Inc Earnings Call Transcript - GuruFocus
Q3 2025 Lisata Therapeutics Inc Earnings Call Transcript - GuruFocus
Is Lisata Therapeutics (LSTA) Stock Slowing Down | Price at $5.01, Down 0.20%Investment Signal Network - Newser
LSTA Should I Buy - Intellectia AI
Lisata Therapeutics Delays Tender Offer Launch in Merger - The Globe and Mail
Lisata Therapeutics and Kuva Labs extend tender offer deadline to April 13 - Investing.com Australia
Lisata Therapeutics (LSTA) and Kuva Labs delay tender offer launch to April 13 - Stock Titan
Atlantic International Corp. and its subsidiary Lyneer officially filed a lawsuit with a New York court on April 1, accusing Spp Credit Advisors of misconduct. - bitget.com
According to the latest filing submitted to the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Lisata Therapeutics Inc (hereinafter referred to as "Lisata Therapeutics") and its partner Kuva Labs have jointly decided to officially ext - Bitget
Lisata extends commencement date for tender offer under merger agreement to April 13 - TradingView — Track All Markets
Lisata Therapeutics Inc (LSTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):